Fund flows
Foreigners: Foreign institutional investors were net buyers of stocks (Rs186 crore). They bought shares worth Rs12,833 crore.
 
 
Indians: Domestic institutional investors were also net buyers of stocks (Rs1,936 crore). They bought shares worth Rs9,059 crore.

User

Government skips one stage, BS-VI emission norms from 2020 onwards
New Delhi : The central government on Wednesday decided to skip one stage and implement directly Bharat Stage (BS) VI norms from April 1, 2020.
 
Implementation of BS V emission norms will be skipped and the government will come out with a notification in this regard soon, it was decided at a meeting chaired by Road Transport & Highways and Shipping Minister Nitin Gadkari. 
 
The Auto Fuel Policy had recommended implementation of BS-VI norms by 2024. Earlier in the draft notification by the ministry, the date was advanced to April 1, 2021 and now it has been further advanced to April 1, 2020.
 
The others who attended the meeting are Heavy Industries and Public Enterprises Minister Anant Geete, Environment, Forest and Climate Change Minister Prakash Javadekar and Petroleum and Natural Gas Minister Dharmendra Pradhan. 
 
According to Pradhan, public sector oil companies will invest about Rs.28,750 crore for switching over to BS-VI auto fuels.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

USFDA warns Cadila on lack of audit trails, torn notebooks, product mix-ups
Chennai : Torn notebook recording deficiencies, lack of batch manufacturing records, use of unofficial notebooks, lack of audit trails on operation of computer systems, product mix-ups due to manufacturing deficiencies are some of the violations found by USFDA at Cadila Healthcare Ltd's two plants.
 
The United States Food and Drug Administration (USFDA) on December 23, 2014 had issued a warning letter to Cadila Healthcare for various deficiencies in its production process and documentation at its two plants in Gujarat.
 
The warning letter was addressed to Pankaj R Patel, chairman and managing director, Cadila Healthcare.
 
The USFDA found significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.
 
"Our investigators found several plastic bags filled with paperwork and other scrapped items in the scrap yard. One item was a torn notebook of deficiencies recorded during review of your batch manufacturing records," the regulator said in its letter.
 
According to USFDA, the Indian company did not explain why production personnel used unofficial paper for documenting relevant CGMP data.
 
The USFDA also said Cadila Healthcare failed to control the use of computerised systems in the quality control laboratory.
 
"Our inspection team found that the laboratory manager had the ability to delete data from the Karl Fischer Tiamo software. During our limited review of your Karl Fischer data, we found that one file had been deleted. 
 
"However, because the audit trail function for the Karl Fischer Tiamo software was not activated, and because eight different analysts share a single username and password, you were unable to demonstrate who performed each operation on this instrument system," the warning letter notes.
 
"You do not have a record of the acquisition of all data, nor do you have records of changes to or modifications of such data," the letter added.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)